Braveheart Bio targets up to $318.8M in US IPO

Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise up to $318.8 million through an initial public offering in the US. This filing adds to a growing pipeline of listings within the biotech sector. The company aims to secure this funding to support its operations as it moves forward with its clinical-stage developments, marking a significant financial milestone for the a16z-backed firm in the public equity markets.